Tomoaki Matsumura, Michiko Sonoda, Kenichiro Okimoto, Hang Viet Dao, Satsuki Takahashi, Naoki Akizue, Ryosuke Horio, Chihiro Goto, Akane Kurosugi, Tatsuya Kaneko, Yuki Ohta, Takashi Taida, Atsuko Kikuchi, Mai Fujie, Jun Kato, Naoya Kato
BACKGROUND: Vonoprazan, a potassium-competitive acid blocker, demonstrates more potent acid inhibition than proton pump inhibitors (PPIs). This study aimed to evaluate the effect of vonoprazan in patients with unproven gastroesophageal reflux disease (GERD) by comparing patients with vonoprazan-refractory heartburn with those with PPI-refractory heartburn. METHODS: This study included 104 consecutive patients with vonoprazan- or PPI-refractory heartburn (52 patients each), no erosive esophagitis on endoscopy and who underwent combined multichannel intraluminal impedance-pH (MII-pH) testing with vonoprazan/PPI discontinuation...
April 15, 2024: Digestive Diseases and Sciences